The Europe Rare Diseases Treatment Market is expected to witness market growth of 12% CAGR during the forecast period (2022-2028).
Manufacturers of the new drugs benefit from tax breaks, quick approvals, and other research grants, allowing for much more innovation. Product development can lead to technological products and medical or pharmaceutical innovations that can be utilized to expand into new markets. The general public is conscious of such rare diseases, and this awareness is growing as a result of the government's efforts.
Adding to this scenario, cost recovery strategies in developed nations are driving up the demand for rare disease treatments. Ignorance of rare diseases can be more expensive than research aimed at increasing knowledge. Rare genetic diseases frequently affect patients at a young age and reduce life expectancy, so affected individuals may need health care for the rest of their lives.
The adoption of more advanced home healthcare equipment, as well as the launch of innovative value-based payment and service models, have created a profitable investment opportunity in U.K. healthcare. As the region's healthcare industry expands, the regional market players are contributing heavily in the development of advanced rare diseases treatment in the region. With R&D corporation tax relief, the UK encourages investment as well as rewards innovation in the healthcare life sciences & technology sector. As a result of this, vendors are increasingly investing in the Europe region.
The Germany market dominated the Europe Rare Diseases Treatment Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $16,772 million by 2028. The UK market is expected to experience a CAGR of 11.1% during (2022 - 2028). Additionally, The France market is expected to exhibit a CAGR of 12.9% during (2022 - 2028).
Based on Distribution Channel, the market is segmented into Specialty Pharmacy, Hospital Pharmacy, and Online Pharmacy. Based on Route of Administration, the market is segmented into Injectable, Oral, and Others. Based on Therapeutic Area, the market is segmented into Cancer, Cardiovascular Conditions, Infectious Diseases, Musculoskeletal Conditions, Endocrine Disorders, Metabolic Disorders, Hematologic Disorders, Neurological Conditions, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Merck Group, Bristol Myers Squibb Company, Pfizer, Inc., AstraZeneca PLC, Takeda Pharmaceutical Company Limited and PTC Therapeutics, Inc.
Manufacturers of the new drugs benefit from tax breaks, quick approvals, and other research grants, allowing for much more innovation. Product development can lead to technological products and medical or pharmaceutical innovations that can be utilized to expand into new markets. The general public is conscious of such rare diseases, and this awareness is growing as a result of the government's efforts.
Adding to this scenario, cost recovery strategies in developed nations are driving up the demand for rare disease treatments. Ignorance of rare diseases can be more expensive than research aimed at increasing knowledge. Rare genetic diseases frequently affect patients at a young age and reduce life expectancy, so affected individuals may need health care for the rest of their lives.
The adoption of more advanced home healthcare equipment, as well as the launch of innovative value-based payment and service models, have created a profitable investment opportunity in U.K. healthcare. As the region's healthcare industry expands, the regional market players are contributing heavily in the development of advanced rare diseases treatment in the region. With R&D corporation tax relief, the UK encourages investment as well as rewards innovation in the healthcare life sciences & technology sector. As a result of this, vendors are increasingly investing in the Europe region.
The Germany market dominated the Europe Rare Diseases Treatment Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $16,772 million by 2028. The UK market is expected to experience a CAGR of 11.1% during (2022 - 2028). Additionally, The France market is expected to exhibit a CAGR of 12.9% during (2022 - 2028).
Based on Distribution Channel, the market is segmented into Specialty Pharmacy, Hospital Pharmacy, and Online Pharmacy. Based on Route of Administration, the market is segmented into Injectable, Oral, and Others. Based on Therapeutic Area, the market is segmented into Cancer, Cardiovascular Conditions, Infectious Diseases, Musculoskeletal Conditions, Endocrine Disorders, Metabolic Disorders, Hematologic Disorders, Neurological Conditions, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Merck Group, Bristol Myers Squibb Company, Pfizer, Inc., AstraZeneca PLC, Takeda Pharmaceutical Company Limited and PTC Therapeutics, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Drug Type- Biologics
- Biosimilar
- Small Molecule
- Specialty Pharmacy
- Hospital Pharmacy
- Online Pharmacy
- Injectable
- Oral
- Others
- Cancer
- Cardiovascular Conditions
- Infectious Diseases
- Musculoskeletal Conditions
- Endocrine Disorders
- Metabolic Disorders
- Hematologic Disorders
- Neurological Conditions
- Others
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- AbbVie, Inc.
- F. Hoffmann-La Roche Ltd.
- Bayer AG
- Novartis AG
- Merck Group
- Bristol Myers Squibb Company
- Pfizer, Inc.
- AstraZeneca PLC
- Takeda Pharmaceutical Company Limited
- PTC Therapeutics, Inc.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. Europe Rare Diseases Treatment Market by Drug Type
Chapter 5. Europe Rare Diseases Treatment Market by Distribution Channel
Chapter 6. Europe Rare Diseases Treatment Market by Route of Administration
Chapter 7. Europe Rare Diseases Treatment Market by Therapeutic Area
Chapter 8. Europe Rare Diseases Treatment Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- AbbVie, Inc.
- F. Hoffmann-La Roche Ltd.
- Bayer AG
- Novartis AG
- Merck Group
- Bristol Myers Squibb Company
- Pfizer, Inc.
- AstraZeneca PLC
- Takeda Pharmaceutical Company Limited
- PTC Therapeutics, Inc.
Methodology
LOADING...
